Samplix Secures €25M for Antibody Discovery

Finding rare cells that make useful antibodies can slow the development of new medicines. Danish biotech Samplix is raising financing to expand a platform that screens cells by their biological behaviour.

What happened

Samplix announced the €25 million first close of a financing round led by WLanholding. The amount consists of approximately €3 million in new capital and €22 million in conversions of existing shareholder convertible bonds. The round remains open, with a target of €30 million.

The company develops Xdrop, a droplet-microfluidics platform that isolates living cells into tiny reaction environments. Researchers can then screen those cells for desired characteristics, including the production of antibodies against challenging targets.

The financing is intended to support commercial expansion, research and development, and wider deployment of the Xdrop system in antibody-discovery workflows.

It would be misleading to describe the full €25 million as newly received cash: most of the first close converts previously outstanding financing instruments.

Why it matters

Drug discovery often depends on finding a small number of cells with particularly valuable properties. Screening based on actual cellular function can complement approaches that focus primarily on binding or genetic sequence.

Samplix's tools could help pharmaceutical teams identify promising candidates for targets that are difficult to study with conventional methods, including some membrane proteins. Commercial success will depend on throughput, reproducibility, compatibility with laboratory workflows and cost.

The bigger picture

Biotech infrastructure companies can create value by improving the tools researchers use rather than developing medicines themselves. Samplix's financing illustrates that opportunity, while its structure shows why headline funding figures must be separated into fresh capital and converted obligations.